Assess whether related-party sales should be backed out of valuation (afa30f)

SITUATION Regulatory-approval critical-path calendar arrived with a QoE that cannot tie revenue to bank cash for buy-side QoE lead. That is a M&A Due Diligence Legal, IP, and Regulatory decision on related-party sales should be in a health-system acquiring a specialty practice.

DECISION Buy-side QoE lead in a health-system acquiring a specialty practice must choose Proceed / Reprice / Walk / Hold using regulatory-approval critical-path calendar after a QoE that cannot tie revenue to bank cash.

HYPOTHESES TO TEST 1. Buy-side QoE lead can defend Proceed from regulatory-approval critical-path calendar after a QoE that cannot tie revenue to bank cash in a M&A Due Diligence challenge. 2. Buy-side QoE lead cannot defend Proceed from regulatory-approval critical-path calendar; Reprice is what the extract actually supports after a QoE that cannot tie revenue to bank cash. 3. A QoE that cannot tie revenue to bank cash never reached the population in regulatory-approval critical-path calendar — reopen intake, do not close related-party sales should be. 4. Two facts in regulatory-approval critical-path calendar after a QoE that cannot tie revenue to bank cash conflict for buy-side QoE lead; hold this Legal, IP, and Regulatory file.

ANALYSIS REQUIRED 1. Separate a one-off add-back from a recurring earnings issue in regulatory-approval critical-path calendar. 2. Map reps, earnout mechanics, and integration risk a health-system acquiring a specialty practice would inherit. 3. Tie quality-of-earnings, working-capital, and contingent items in regulatory-approval critical-path calendar to related-party sales should be. 4. For this M&A Due Diligence Legal, IP, and Regulatory file, read regulatory-approval critical-path calendar against a QoE that cannot tie revenue to bank cash and write the one fact that would move related-party sales should be for buy-side QoE lead.

RECOMMENDATION Do not close related-party sales should be from a generic M&A Due Diligence playbook. Regulatory-approval critical-path calendar after a QoE that cannot tie revenue to bank cash either supports Proceed for buy-side QoE lead in a health-system acquiring a specialty practice, supports Reprice, or is incomplete — in which case buy-side QoE lead must do not proceed, reprice, or walk on a quality-of-earnings fact the packet does not carry.

COMMAND RETURNS - Bottom-line M&A Due Diligence option on related-party sales should be, then the evidence in regulatory-approval critical-path calendar, then the action for buy-side QoE lead - Hypothesis scorecard against regulatory-approval critical-path calendar: supported / rejected / untestable - Named option among Proceed, Reprice, Walk and the fact that kills the others - Owner and next date for buy-side QoE lead in a health-system acquiring a specialty practice